Estimating Societal Cost of Illness and Patients’ Quality of Life of Duchenne Muscular Dystrophy in Egypt

Shehata, Zahraa Hassan; Rabea, Hoda; Sherif, Rasha El; Abdelrahim, Mohamed E. A.; Dawoud, Dalia

doi:10.1016/j.vhri.2022.08.006

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…et al, (2015) in Egypt reported that direct costs ranged from 15-1006 Egyptian pounds per month (208.33 ± 166.197) among psoriatic patients. The direct medical cost accounted for more than three quarters of total cost (75.8%) comparing to only 18.2% due to transportation (Direct non-medical cost) [12] . Direct cost of illness is not well adressed but results of the present study showed that financial burden among vitiligo patients is similar to other chronic skin diseases with visible symptoms such as posoraisis.…”

Section: Direct Cost Of Vitiligomentioning

confidence: 99%

“…Data was collected by interviewing patients using a questionnaire consisted of four sections; the first section included the socio-demographic data of the patients: age, sex, residence, marital status, education, occupation, and special habits e.g., smoking, the second section contained the vitiligo history of the patients: type of vitiligo, duration, type of treatment, compliance to treatment, the third section included vitiligo life quality index (VLQI) which is a specific quality of life scale for vitiligo [11] . The fourth section was directed to estimate the direct cost of illness of vitiligo based on the patients' self-reported expenses in the prior month [12] .…”

Section: Study Toolmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life and direct cost of illness among vitiligo patients in Tanta University Hospitals, Egypt

Korashy,

Elgarhy,

Younis

et al. 2023

Int. J. Adv. Community Med.

View full text Add to dashboard Cite

Background: Vitiligo is the most common pigmentary disorder affecting skin melanocytes leading to skin depigmentation. It does not only affect the patients' appearance, but also affects their quality of life, compromising their mental health, social and work lives. Vitiligo has a significant financial impact due to the chronic nature and the long treatment course. Objectives:1. To assess quality of life of vitiligo patients. 2. To estimate direct cost of illness of vitiligo and whether it represents a financial burden on patients. Methods: A cross sectional study was carried out at the vitiligo unit of the Dermatology and Venerology Department in Tanta University Hospitals from October 2021 till March 2022. It included 66 vitiligo patients. A questionnaire was used to interview patients which consisted of the following parts (1) Socio demographic data. (2) Disease profile of patients. (3) Vitiligo life quality index (VLQI). (4) Direct cost of illness. Results: 78.9% of patients suffered from quality of life impairment. Patients suffering from moderate effect represented 21.2%, followed by very large and extreme effect represented 19.7% each and patients suffered slight effect represented 18.2%. Meanwhile, only 21.2% of patients reported no affection. The mean direct cost of illness was 340.9 ± 280.4 Egyptian pounds per month. Conclusion: Most vitiligo patients suffered some degree of quality of life impairment. Nearly half of them reported having extreme financial impairment.

show abstract

Section: Direct Cost Of Vitiligomentioning

confidence: 99%

Section: Study Toolmentioning

confidence: 99%

Quality of life and direct cost of illness among vitiligo patients in Tanta University Hospitals, Egypt

Korashy,

Elgarhy,

Younis

et al. 2023

Int. J. Adv. Community Med.

View full text Add to dashboard Cite

show abstract

Early Cost-Utility Analysis of Ataluren and Eteplirsen in the Treatment of Duchenne Muscular Dystrophy in Egypt

Shehata,

Metry,

Rabea

et al. 2023

Value in Health Regional Issues

View full text Add to dashboard Cite

Role of Physical Therapy Intervention and Gene Therapy on Muscular Dystrophies, Current Status and Future Perspectives: A Narrative Review

Abid,

Shah,

Ahmed

et al. 2024

PJHS

View full text Add to dashboard Cite

Muscular dystrophies form a collection of genetic disorders marked by progressive muscle weakness and degeneration. The identification of the majority of responsible genes has enabled precise diagnosis and subtype-specific anticipatory care. Over the years, various therapies, encompassing genetic, cellular, and pharmacological approaches, have emerged for muscular dystrophies. This narrative review thoroughly explores the ongoing developments in muscular dystrophy therapeutics, including antisense therapy, CRISPR, gene replacement, cell therapy, based gene therapy Adeno-associated viral vector (AAV), and disease-modifying small molecule compounds. The review is particularly significant as it reflects advancements in supportive medicine that have altered the standard of care, leading to an overall improvement in the quality of life, clinical course and survival for affected individuals. In this study, our focus is on the clinical manifestations, molecular pathogenesis, diagnostic strategies, and therapeutic advancements related to this group of conditions. The study involved the review of 20 pertinent English-language articles, publications, reports, and online resources.

show abstract

Estimating Societal Cost of Illness and Patients’ Quality of Life of Duchenne Muscular Dystrophy in Egypt

Cited by 5 publications

References 20 publications

Quality of life and direct cost of illness among vitiligo patients in Tanta University Hospitals, Egypt

Quality of life and direct cost of illness among vitiligo patients in Tanta University Hospitals, Egypt

Early Cost-Utility Analysis of Ataluren and Eteplirsen in the Treatment of Duchenne Muscular Dystrophy in Egypt

Role of Physical Therapy Intervention and Gene Therapy on Muscular Dystrophies, Current Status and Future Perspectives: A Narrative Review

Contact Info

Product

Resources

About